1.32
-0.02 (-1.49%)
| Previous Close | 1.34 |
| Open | 1.34 |
| Volume | 5,107,656 |
| Avg. Volume (3M) | 2,373,772 |
| Market Cap | 1,047,793,344 |
| Price / Sales | 1.52 |
| Price / Book | 0.790 |
| 52 Weeks Range | |
| Earnings Date | 29 Oct 2025 |
| Profit Margin | -5.66% |
| Operating Margin (TTM) | -44.79% |
| Diluted EPS (TTM) | -0.060 |
| Quarterly Revenue Growth (YOY) | -13.70% |
| Total Debt/Equity (MRQ) | 37.58% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | -182.48 M |
| Levered Free Cash Flow (TTM) | -107.74 M |
| Return on Assets (TTM) | -8.20% |
| Return on Equity (TTM) | -3.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Opko Health, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.38 |
|
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 46.81% |
| % Held by Institutions | 30.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Awm Investment Company, Inc. | 30 Sep 2025 | 2,200,000 |
| Y.D. More Investments Ltd | 30 Sep 2025 | 1,499,118 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 2.25 (Barrington Research, 70.46%) | Buy |
| Median | 1.93 (46.21%) | |
| Low | 1.60 (Jefferies, 21.21%) | Hold |
| Average | 1.93 (46.21%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 1.41 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 31 Oct 2025 | 1.60 (21.21%) | Hold | 1.36 |
| Barrington Research | 30 Oct 2025 | 2.25 (70.45%) | Buy | 1.46 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Nov 2025 | Announcement | OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 13 Nov 2025 | Announcement | NextPlat Reports Third Quarter 2025 Results |
| 29 Oct 2025 | Announcement | OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results |
| 29 Oct 2025 | Announcement | OPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications |
| 28 Oct 2025 | Announcement | OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers |
| 22 Oct 2025 | Announcement | OPKO Health to Report Third Quarter 2025 Financial Results on October 29 |
| 15 Sep 2025 | Announcement | Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |